4.7 Review

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.11.014

关键词

aortic stenosis; cardiovascular disease; lipoprotein(a); metabolism; pathophysiology; therapy

资金

  1. NCATS NIH HHS [UL1 TR001873, KL2 TR001874] Funding Source: Medline
  2. NHLBI NIH HHS [R01 HL106579, R35 HL135833, R01 HL078610, R35 HL135737, P01 HL088093, R01 HL136098, R01 HL119828, R01 HL128550, P01 HL136275] Funding Source: Medline

向作者/读者索取更多资源

Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). Specific therapies to address Lp(a)-mediated CVD and CAVD are in clinical development. Due to knowledge gaps, the National Heart, Lung, and Blood Institute organized a working group that identified challenges in fully understanding the role of Lp(a) in CVD/CAVD. These included the lack of research funding, inadequate experimental models, lack of globally standardized Lp(a) assays, and inadequate understanding of the mechanisms underlying current drug therapies on Lp(a) levels. Specific recommendations were provided to facilitate basic, mechanistic, preclinical, and clinical research on Lp(a); foster collaborative research and resource sharing; leverage expertise of different groups and centers with complementary skills; and use existing National Heart, Lung, and Blood Institute resources. Concerted efforts to understand Lp(a) pathophysiology, together with diagnostic and therapeutic advances, are required to reduce Lp(a)-mediated risk of CVD and CAVD. (c) 2018 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据